On June 8, 2022 The Parker Institute for Cancer Immunotherapy (PICI), a network of the largest concentration of immuno-oncology (IO) expertise in the world, and National Resilience, Inc. (Resilience), a technology-focused biomanufacturing company dedicated to broadening access to complex medicines, reported the launch of a five-year strategic alliance to develop next-generation cancer therapies generated from PICI’s network of leading immunotherapy research centers (Press release, Parker Institute for Cancer Immunotherapy, JUN 8, 2022, View Source [SID1234615777]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Together, PICI and Resilience aim to bring novel cell and gene therapies to market through the creation and incubation of new companies with a commitment of up to $50 million in funding. These startups will leverage groundbreaking technologies from across the PICI Network and have direct access to Resilience’s biomanufacturing capacity, capability, and know-how.
"This strategic alliance is representative of the transformative growth underway at PICI as we take our vision to the next level with new company investments and incubation," stated Sean Parker, PICI founder and chairman. "Now, in collaboration with Resilience, we are closing the loop with access to critical biological manufacturing that will further accelerate our mission of delivering breakthrough immune therapies to patients and transforming all cancers into curable diseases."
Under the agreement, Resilience will also collaborate with PICI Network investigators on challenges related to biomanufacturing and novel treatment modalities. As PICI’s first valued manufacturing partner for complex modalities Resilience will be well positioned to work with PICI Affiliated Partners (PICI-invested companies, PICI Network Institutions, and Network Investigators) on developing enabling biomanufacturing technology and to lower the barriers for technology access across the PICI network and more broadly within the therapeutic development community.
"By combining our organizations’ capabilities in drug discovery, development and cutting-edge biomanufacturing technologies, we aim to advance a new wave of treatments to patients in need," said Rahul Singhvi, ScD, Chief Executive Officer of Resilience. "This alliance with PICI will demonstrate the power of new business models in finding and advancing cancer therapies."
Resilience and PICI will establish a Joint Steering Committee to approve investments and new company opportunities, monitor and track the progress of alliance portfolio companies, and identify innovation challenge focus areas, among other duties.
"Through this strategic alliance, we have an opportunity to deliver unparalleled access to innovation in cancer immunotherapy and manufacturing across PICI-invested companies and the PICI Network," stated PICI Chief Scientific Officer, John Connolly, PhD. "The combination of PICI’s bench-to-market-to-patient philosophy and Resilience’s end-to-end biomanufacturing solutions support novel idea generation and development, delivering cutting-edge therapeutics to patients with cancer faster."
"By working closely with PICI Network Investigators, we can develop the advanced manufacturing technologies needed to bring cutting-edge therapies to patients that need them," said Rich Stoner, PhD, Chief Scientific Officer, Resilience. "Our goal is to ensure these therapies can be made at the quality and scale required to bring transformative immune therapies to people with cancer."